Author: Ravi Shankar

Geochemical and geophysical results expand known target footprints and support district-scale exploration potential across TDG’s 100%-owned Toodoggone mineral claims

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — TDG Gold Corp. (“TDG” or the “Company”) (TSXV: TDG | OTCQX: TDGGF) reports that interim results from its 2026 regional exploration program have expanded and better-defined exploration target areas at Baker–North Quartz, Black Gossan and Price–Trident. Each target area is characterized by kilometre-plus-scale geophysical responses or groupings of responses, located within TDG’s 100%-owned mineral claims in a corridor stretching northwest from Amarc-Freeport’s Aurora gold-rich copper porphyry discovery in BC’s Toodoggone District.

The results extend the exploration footprint beyond historical showings and support evaluating multiple potential mineralizing centres across an approximately 15-kilometre prospective corridor extending northwest of the Aurora Complex (Figure 1). Integrated soil geochemistry has identified additional gold- and copper-anomalous areas, the potential of which is supported by geophysical anomalies, providing a common technical basis for comparing and prioritizing opportunities across the corridor.

Key results

• Baker–North Quartz: Gold and copper soil anomalies extend across several kilometres, while preliminary modelling identifies separate induced polarization (“IP”) chargeability responses distributed over an approximately 3.5-kilometre span. These responses extend the area of interest beyond the historical Baker high-grade gold-copper-silver mine workings and are not interpreted to be a single continuous body, rather a complex of anomalies.
• Black Gossan: Preliminary modelling outlines a pronounced chargeability response with an approximately 2.1-kilometre horizontal extent in section, associated with relatively low resistivity, mapped alteration, soil geochemistry anomalies and magnetic contrasts.
• Price–Trident: Copper and gold soil enrichment, intrusive geology and a local magnetic feature are associated with separate shallow and deeper chargeability responses across an approximately 1.45-kilometre span.

Remaining 2026 fieldwork, outstanding assays and final geophysical interpretations will support target ranking, with emphasis on geological setting, geochemical coherence, potential for near-surface mineralization and support from multiple independent datasets.

“The significance of this work is the combination of scale and multiple opportunities within one wholly-owned corridor,” said Paul Geddes, TDG’s SVP Business Development & Strategy. “A consistent technical framework allows us to compare those opportunities and identify where the strongest evidence comes together. That provides a better basis for selecting where to focus the next stage of exploration.”

A Corridor-Scale Strategy for Target Prioritization

The 2026 program integrates soil geochemistry, direct-current induced polarization (“DCIP”) and passive magnetotellurics across TDG’s 100%-owned mineral claims covering an area that encompasses TDG’s mineral-resource-stage Shasta project (PEA initiated June 2026), Aurora West and Baker, and extends as far north as the Saunders target (Figure 1). It represents the first comprehensive assessment of the broader corridor using consistent geochemical and geophysical coverage, looking beyond historical showings to determine whether they represent isolated occurrences or surface expressions of larger mineralized systems.

The principal exploration model is a corridor containing multiple intrusive-related hydrothermal centres and associated epithermal systems. Of particular interest are telescoped environments, where younger, shallower gold-rich mineralization may overprint earlier copper–gold porphyry system(s).

The regional alignment of Aurora West, Shasta, Newberry, Price–Trident, Black Gossan, Baker–North Quartz, and emerging targets farther north, defines a northwest-trending corridor with demonstrated copper, gold and silver endowment. TDG’s integrated approach is intended to identify the strongest near-surface opportunities and determine where multiple datasets support priority targets for potential drill testing.

Soil Survey: Expanding Target Footprints

3,455 soil samples have been collected against an expanded plan of approximately 5,000 samples.

Phase I established regional reconnaissance coverage using 200-by-200-metre and 200-by-400-metre sampling. Its purpose was to evaluate previously underexplored ground and identify new gold, copper and pathfinder-element anomalies.

Phases II and III are providing detailed follow-up through predominantly 100-by-100-metre sampling, locally with 50-by-50-metre infill, in areas of interest. This closer-spaced coverage is designed to refine anomaly boundaries, establish internal trends and identify the best locations for potential drill testing.

Results received to date demonstrate that the geochemical footprints around several historical occurrences are substantially broader than the individual showings that originally defined them. Around Baker–North Quartz, anomalous gold and copper values are distributed across several kilometres, extending the target well beyond the former Baker mine workings. Additional anomalous areas have been identified through Price–Trident and northward along the corridor.

The soil data also identify new areas of gold and copper enrichment where no established target had previously been defined (Figure 1). These anomalies may represent surface expressions of previously unrecognized mineralizing centres and allow TDG to evaluate the continuity of prospective trends between known occurrences.

North of Trident, emerging soil anomalies extend the investigation toward the property boundary and occur along the broader regional trend that continues toward Finlay Minerals’ (Freeport JV) neighbouring “Gold” target. The neighbouring occurrence is referenced for regional geological context only and is not necessarily indicative of mineralization on TDG’s property.

Geophysics: Investigating the Systems Below Surface

The 2026 geophysical program comprises approximately 55 line-kilometres of DCIP across eight regional lines, with approximately 48 line-kilometres completed and one seven-kilometre line remaining. The lines provide consistent, large-area coverage across the corridor, extending beyond individual historical showings.

The program also includes ground-based passive magnetotelluric data, acquired to provide complementary information on subsurface resistivity and the possible deeper architecture of the mineralizing systems.

Integrated IP, resistivity and magnetotelluric data help evaluate potential sulphide-bearing rocks, alteration, intrusive contacts and structures below surface. Preliminary modelling shows associations with known occurrences and soil anomalies, allowing TDG to assess target scale and prioritize areas supported by multiple independent datasets for potential drilling.

Target Findings

Baker–North Quartz: Expanded Footprint and Multiple Responses

The 2026 soil survey has expanded the gold and copper footprint around Baker–North Quartz to several kilometres, well beyond the area historically explored around the Baker veins.

Preliminary DCIP inversion modelling identifies several separate chargeability responses across an approximately 3.5-kilometre span. These responses occur within a broader magnetic low containing distinct internal magnetic features. They are not presently interpreted as one continuous body but collectively demonstrate that the broader Baker–North Quartz area contains multiple subsurface targets.

Baker is historically recognized as an epithermal gold–silver system with some porphyry affinities. Previous drilling also demonstrated that mineralization extends beyond the high-grade veins. In 2023, resampling of historical drill hole BK86-10 returned 100.3 metres grading 1.07 grams per tonne (“g/t”) gold, 0.10% copper and 4 g/t silver, including 37.4 metres grading 2.69 g/t gold and 0.19% copper. Reported drill intervals are core lengths. Estimated true widths are 40–60% of core length, and historical core recovery is unknown. Additional information is available in TDG’s August 15, 2023 news release.

The expanded soil footprint, multiple IP responses and historical broad mineralized drill intersections support evaluating Baker as a potentially larger hydrothermal system than indicated previously.

Black Gossan: Kilometre-Scale Subsurface Response

Preliminary DCIP modelling identifies a pronounced chargeability response over an approximately 2.1-kilometre horizontal extent in section, accompanied by relatively low resistivity.

The response is substantially larger than the historical surface occurrence and is associated with mapped alteration, anomalous soil geochemistry and magnetic contrasts. This combination supports the interpretation of a potentially extensive sulphide-bearing hydrothermal system.

Further interpretation will focus on identifying the most prospective near-surface portion of the response and distinguishing possible copper-bearing mineralization from a predominantly pyritic alteration envelope. The extent of the geophysical response does not necessarily represent a mineralized or economic deposit footprint.

Price–Trident: Coincident Geochemical and Geophysical Target

The Price–Trident area contains copper and gold soil enrichment associated with intrusive geology and a local magnetic feature. Preliminary modelling identifies separate shallow and deeper chargeability responses across an approximately 1.45-kilometre span in the broader Price–Trident sector.

The spatial relationship between the geochemistry, geology, magnetics and DCIP supports evaluating Price–Trident as an intrusive-related hydrothermal system with potential for near-surface copper–gold mineralization and associated epithermal mineralization.

The 2026 program has improved the definition of this target and provides a framework for locating the strongest convergence of surface geochemistry and subsurface geophysics.

Greater Shasta–Newberry (GSN): Evaluating Growth and Nearby Targets

In the GSN area, detailed soil sampling is improving coverage around the existing Shasta epithermal gold–silver mineral resource. The objective is to assess whether geochemical patterns, geological structures and geophysical responses identify opportunities to extend mineralization beyond the areas tested by historical and recent drilling.

Newberry remains an undrilled target situated along the same broader corridor as Shasta. Its multi-element soil signature, structural position and magnetic character support continued evaluation as a potential epithermal or intrusive-related target.

The integrated regional program provides, for the first time, a common dataset with which to assess Shasta, Newberry and the intervening ground. This is intended to help determine whether opportunities exist for resource growth at Shasta, nearby satellite mineralization or additional mineralizing centres along trend.

Emerging Regional Targets

Reconnaissance soil sampling has identified additional anomalous areas away from the principal historical showings. Follow-up work is evaluating these new targets based on their gold, copper and pathfinder-element signatures, geological setting, magnetic character and proximity to DCIP responses.

These areas remain at an early stage, but they expand the Company’s target inventory and demonstrate the benefit of assessing the entire corridor rather than limiting exploration to known occurrences.

Next Steps: Target Ranking and Selection

Remaining soil assays, infill sampling, geological mapping and final DCIP, resistivity, magnetic and magnetotelluric interpretations will be combined into a corridor-wide target-ranking framework.

Targets will be evaluated according to the strength, size and coherence of their geochemical response; interpreted depth and geometry of geophysical features; geological and structural setting; potential for near-surface mineralization; and the degree of agreement between independent datasets.

The objective is to develop a ranked portfolio from which to select targets for potential drill testing of:

• extensions to known mineralized systems, including Baker and Shasta;
• potential near-surface, gold-rich telescoped porphyry systems, using Aurora as a regional exploration model;
• near-surface, bulk-tonnage epithermal gold–silver opportunities; and
• potential new mineralizing centres identified through regional exploration.

TDG expects the completed program to provide the technical basis for selecting and sequencing follow-up ahead of the 2027 field season, with priority given to targets supported by the strongest combination of geological, geochemical and geophysical evidence.

Soil Sampling, Analytical Methods and Quality Assurance/Quality Control

Soil samples were collected predominantly from the B-horizon by trained field personnel using standardized procedures. Samples followed documented chain of custody between collection, processing and delivery to the analytical laboratory.

Samples were submitted to ALS Canada Ltd. (“ALS”) in Kamloops, British Columbia, for preparation and to ALS in Vancouver, British Columbia, for analysis.

Analysis utilized method AuME-ST43, comprising aqua-regia extraction of a 25-gram aliquot followed by inductively coupled plasma mass spectrometry and inductively coupled plasma atomic emission spectroscopy for gold and multiple elements. The method provides a lower gold detection limit of 0.1 parts per billion. Aqua regia provides a partial extraction, and reported results may not represent the total concentration of certain elements in the sample.

Quality assurance and quality control (“QA/QC”) are maintained internally by ALS through the use of certified reference materials, blanks and duplicates. TDG maintains an additional QA/QC program through the blind insertion of certified reference materials, blank samples and duplicate samples into the analytical sequence. If a QA/QC sample returns a result outside acceptable limits, an investigation is initiated and, where warranted, samples associated with the affected batch are reanalyzed.

Technical Disclosure

Soil anomalies identify areas of relative geochemical enrichment but do not establish the presence, dimensions, grade or continuity of mineralization. Geophysical anomalies may have multiple geological causes. Chargeability responses can reflect non-economic sulphides, including pyrite, and preliminary inversion geometries remain subject to refinement.

The exploration targets discussed in this release, other than the existing Shasta mineral resource, are conceptual in nature. There has been insufficient exploration to define mineral resources at these targets, and it is uncertain whether further exploration will result in the discovery of a mineral resource.

References to nearby deposits, discoveries and occurrences are provided solely for geological context and are not necessarily indicative of mineralization on TDG’s properties.

Qualified Person

Exploration activities at the Toodoggone Properties are overseen by Paul Geddes, P.Geo. In accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo., is the Qualified Person for the Toodoggone Projects and has written, validated and approved the technical and scientific content of this news release. The Company adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting the exploration activities on its projects.

About TDG Gold Corp.

TDG Gold Corp. is a mineral exploration company focused on advancing its gold, silver and copper projects in British Columbia, Canada. The Company’s projects include Aurora West, the Shasta gold–silver deposit, the Baker Complex, the Mets prospect and the Anyox copper project.

TDG’s strategy is to create shareholder value through disciplined, capital-efficient exploration, technical evaluation, resource growth and advancement of its mineral projects.

ON BEHALF OF THE BOARD

Fletcher Morgan
Chief Executive Officer

For further information contact:
TDG Gold Corp.
Telephone: +1.604.536.2711
Email:info@tdggold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This news release contains forward-looking information and forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. Forward-looking statements relate to future events or future performance and reflect management’s current expectations, estimates, projections, assumptions and beliefs as of the date of this news release.

Forward-looking statements are often identified by words and expressions such as “continue”, “expect”, “is intended to”, “is designed to”, “objective”, “potential”, “evaluate”, “identify”, “prioritize”, “refine”, “select” and “support”, variants of these words and similar expressions, including the negative forms thereof, that certain events or conditions “may” or “will” occur.

Forward-looking statements in this news release include, without limitation, statements regarding: completion and results of the remaining 2026 soil sampling, DCIP surveys, receipt of outstanding assays, geological mapping and final geophysical interpretations; the refinement of anomaly boundaries and identification of priority near-surface targets; the integration and interpretation of geological, geochemical and geophysical information and whether such information will identify targets warranting follow-up or potential drill testing; the evaluation of Baker–North Quartz as a potentially larger hydrothermal system than previously indicated; the interpretation of Black Gossan as a potentially extensive sulphide-bearing hydrothermal system and the identification of its most prospective near-surface portion and differentiation of possible copper-bearing mineralization from predominantly pyritic alteration; the evaluation of Price–Trident as an intrusive-related hydrothermal system with potential for near-surface copper–gold mineralization and associated epithermal mineralization; the continued evaluation of Newberry as a potential epithermal or intrusive-related target; whether evaluation of Shasta, Newberry and the intervening ground will identify opportunities for mineral resource growth at Shasta, nearby satellite mineralization or additional mineralizing centres along trend; the evaluation of emerging regional targets; the development and results of the corridor-wide target-ranking framework; the identification, prioritization, ranking, selection and sequencing of targets for follow-up and potential drill testing, including extensions to known mineralized systems, potential near-surface gold-rich telescoped porphyry systems, near-surface bulk-tonnage epithermal gold–silver opportunities and potential new mineralizing centres; whether or not any of the targets identified and prioritized represent mineralizing systems of economic interest; whether the completed 2026 program will provide the technical basis for selecting and sequencing follow-up ahead of the 2027 field season; and the timing and execution of potential 2027 exploration, including drilling, and the results thereof.

Forward-looking statements are based on a number of assumptions, including but not limited to: the accuracy, reliability and representativeness of geological, geochemical and geophysical data, historical information and preliminary interpretations; the completion of remaining fieldwork, laboratory reporting and final geophysical interpretations in time to inform target evaluation and selection ahead of the 2027 field season; the ability of such information to support target evaluation, refinement, ranking and selection; the availability of financing, personnel, contractors, equipment and laboratory services; the receipt and maintenance of required approvals and permits; and favourable site access, weather and operating conditions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation: the risk that remaining fieldwork, outstanding assays or final geophysical interpretations may not support current interpretations or identify targets warranting follow-up; the risk that geological, geochemical or geophysical anomalies may have non-economic causes, including non-economic sulphides such as pyrite; uncertainty as to whether identified anomalies represent mineralized systems or whether further exploration will identify extensions to known mineralized systems, resource growth, satellite mineralization or additional mineralizing centres; the risk that further evaluation may not support current interpretations of Baker–North Quartz, Black Gossan, Price–Trident, Newberry or other regional targets; the risk that target rankings, priorities and interpretations may change as additional information becomes available; the risk that identified or selected targets may not warrant drill testing or may not be drilled; delays, modifications or cancellation of follow-up exploration or potential drilling; the availability of financing; environmental, permitting, regulatory, access, weather and operating risks; and the other risks disclosed in the Company’s public disclosure documents available under its profile on SEDAR+.

The exploration targets discussed in this news release, other than the existing Shasta mineral resource, are conceptual in nature. Geological, geochemical and geophysical anomalies do not establish the presence, dimensions, grade or continuity of mineralization and may have non-economic causes. There has been insufficient exploration to define mineral resources at these targets, and it is uncertain whether further exploration will result in the discovery of a mineral resource. The reported dimensions describe exploration anomalies or groupings of anomalies, not established mineralized dimensions. Geophysical responses can have non-economic causes, including pyrite, and the interpretations remain preliminary.

Although the Company believes the assumptions and expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such statements will prove to be accurate. Readers should not place undue reliance on forward-looking statements. Actual results may differ materially from those anticipated in such statements.

The forward-looking statements contained in this news release are made as of the date hereof and the Company undertakes no obligation to update such statements except as required by applicable securities laws.

Figure 1: 2026 Currently Defined Gold and Copper Soil Anomalies.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7569cc7d-0fe5-4da4-a2e7-6087d4903549

Esper Joins LT350 Board to Advance the Next Generation of Secure, Distributed, AI Infrastructure for Defense and Critical Infrastructure Resilience

BOULDER, Colo., Sept. 23, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology company pursuing a merger that, if completed, would form McCarthy Finney, an AI-native operating company, today announced the appointment of former U.S. Secretary of Defense Mark T. Esper to the LT350 Board of Directors. The appointment represents a pivotal step in LT350’s development as a national security aligned technology company advancing resilient, edge based AI compute for critical government and civil infrastructure. Esper’s leadership and experience strengthens LT350’s strategic perspective as the company advances toward potential commercial and defense deployments.

LT350 is one of three businesses that would combine with Auddia to form McCarthy Finney if Auddia’s announced business combination with Thramann Holdings, LLC (“Thramann Holdings”) is completed.

Secretary Esper’s Perspective on LT350’s Role

“Secure, distributed compute is becoming foundational to America’s military readiness, economic competitiveness, and critical-infrastructure resilience,” said the Honorable Mark T. Esper, PhD, 27th Secretary of Defense. “LT350’s approach to rapidly deployable, community compatible AI infrastructure reflects the kind of innovation our nation needs to strengthen resilience, reduce vulnerabilities, and expand capacity at the edge. I look forward to supporting LT350 as it advances this next generation of infrastructure.”

Why It Matters

LT350’s parking lot canopy based AI datacenter architecture is designed to support emerging federal and allied priorities for distributed secure compute at the edge and the energy resilience required to optimize continuity of critical operations. Esper’s appointment positions LT350 to pursue strategic engagement across defense modernization, critical infrastructure resilience, and energy grid reinforcement while maintaining a clear focus on commercial deployment.

Strengthening LT350’s National Security Positioning

LT350’s modular canopy based AI compute platform is engineered to deliver secure, networked, distributed AI processing across critical infrastructure networks. Esper’s experience leading the Department of Defense and addressing national security and infrastructure modernization priorities provides LT350 with critical perspective on:

• Defense grade infrastructure resilience
• AI-enabled situational awareness and edge compute deployment
• Public-private collaboration in critical infrastructure modernization
• Strategic alignment with emerging U.S. and allied initiatives in distributed inference, autonomous systems, and resilient energy infrastructure

“Mark’s leadership and national security perspective are invaluable as LT350 scales its platform for both commercial and defense applications,” said Jeff Thramann, founder and CEO of Auddia and LT350. “His appointment to the LT350 Board reinforces LT350’s mission to build infrastructure that strengthens resilience across multiple sectors critical to enhancing national security and competitiveness.”

Looking Ahead

LT350 is advancing plans for pilot deployments of its canopy based datacenter infrastructure and intends to pursue initial commercial and defense partnerships following the merger closing. Esper’s appointment to the LT350 Board strengthens LT350’s ability to align its strategy with national security priorities while supporting commercial adoption.

If the pending merger with Thramann Holdings is completed, investors in Auddia will gain exposure to LT350 through McCarthy Finney Inc. (MCFN), and LT350 will operate as a wholly owned subsidiary of MCFN following closing.

About the Merger to form McCarthy Finney (MCFN)

Auddia entered into a definitive merger agreement with Thramann Holdings, LLC on February 17, 2026. If completed, the transaction would combine Auddia with three early-stage, AI-native operating companies wholly owned by Thramann Holdings: LT350, Influence Healthcare, and Voyex. The combined company would be renamed McCarthy Finney Inc. and is expected to trade under the ticker MCFN, subject to applicable approvals and listing requirements. McCarthy Finney would operate as an AI holding company supporting LT350, Influence Healthcare, Voyex, and Auddia with AI and Web3 capabilities.

• LT350 is a distributed AI datacenter company with 14 issued patents and 3 pending patent applications covering its proprietary solar parking lot canopy infrastructure platform. The platform integrates modular battery storage and GPU cartridges into the canopy ceiling to convert the airspace of underutilized parking areas into distributed AI datacenters. LT350 aims to build a secure, low latency, cost effective, and rapidly deployable edge network while supporting local power infrastructure resilience.
• Influence Healthcare is a healthtech company leveraging AI, blockchain, and vertical integration to empower surgeons to drive adoption of value based care (VBC) to the surgical specialties. The Company’s mission is to leverage technology and value based enterprises (VBEs) to build an alternative healthcare system that minimizes the corporate practice of medicine, eliminates administrative waste, and enhances the autonomy and pay of health care providers to empower them to improve quality and return the patient physician relationship to the center of medicine.
• Voyex is a travel services platform that leverages agentic AI, an integrated fintech platform, and utilization of charter and private jet aircraft to significantly improve the travel experience. The Company aims to alleviate the leading pain points for travelers of lengthy flight delays and cancellations.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio identification and classification, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

• Ad-free listening on any AM/FM radio station
• Content skipping across any AM/FM station
• One-touch skipping of entire podcast ad breaks
• Integrated artist discovery experiences

For more information, visit www.auddia.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2025, which was originally filed with the SEC on March 6, 2026, subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time. Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia communicates with investors and the public through its investor-relations website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
www.pcgadvisory.com

• Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12
• Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-1402 in CLE
• IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies
• All other clinical development timelines remain on track

DURHAM, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) — Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).

The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE.

“On behalf of everyone at Immunovant, I want to thank the patients living with CLE who volunteered for this study and the investigators and clinical site teams who conducted it with such care. Their contributions advance our understanding of FcRn inhibition in autoimmune disease and will inform our work going forward,” said Eric Venker, M.D., Pharm.D., Chief Executive Officer of Immunovant.

Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402 across multiple autoimmune diseases with significant unmet need, including Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren’s disease.

About the Proof-of-Concept Study of IMVT-1402 in CLE
The proof-of-concept clinical study (NCT06980805) of IMVT-1402 (imeroprubart) in CLE is a randomized, double-blind, placebo-controlled, global trial that assessed the safety and efficacy of IMVT-1402 in adult patients with CLE. The study enrolled 57 patients. In Period 1, patients were randomized to IMVT-1402 vs. placebo for a 12-week treatment period. The primary endpoint was the percent change from Period 1 baseline in CLASI-A score at Week 12.

About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “can,” “may,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” “design,” “plan,” “intend,” and other similar expressions are intended to identify forward-looking statements. Such forward-looking statements include statements regarding Immunovant’s plans and progress towards developing IMVT-1402 across a broad range of indications. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant’s product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant’s scientific approach, clinical trial design, indication selection, regulatory strategy, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant’s product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of global factors, such as international trade tariffs, geopolitical tensions, and adverse macroeconomic conditions on Immunovant’s business operations and supply chain, including its clinical development plans and timelines; Immunovant’s business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402; Immunovant is at various stages of clinical development for IMVT-1402; and Immunovant will require additional capital to fund its operations and advance IMVT-1402 through clinical development. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s Annual Report on Form 10-K filed with the SEC on May 20, 2026, and Immunovant’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company has qualified to for trading on the OTCQX^® Best Market. Talisker shares will begin trading today on OTCQX under the symbol “TSKFF”.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Trading in non-U.S. North American securities on OTC Markets reached $23.4 billion in the second quarter of 2026, representing an 88.25% increase over Q2 2025. OTC Markets recorded $453.34 billion in total dollar volume in the first half of the year. Canada ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

Terry Harbort, CEO of Talisker stated, “We are pleased to have re-qualified for trading on the OTCQX Market which we anticipate will provide Talisker with wider visibility to the U.S. investment community.”

For further information, please contact:

Lindsay Dunlop
Vice President, Investor Relations
lindsay.dunlop@taliskerresources.com
+1 647 274 8975

About Talisker Resources Ltd.

Talisker (taliskerresources.com) is a junior resource company involved in the exploration and development of gold projects in British Columbia, Canada. Talisker’s flagship asset is the high-grade, fully permitted Bralorne Gold Project where the Company is producing at the Mustang Mine. Talisker projects also include the Ladner Gold Project, an historic high-grade gold mine near Hope, British Columbia, with significant exploration potential, and the Spences Bridge Project, where the Company has a significant landholding in the emerging Spences Bridge Gold Belt, as well as several other early-stage Greenfields projects.

Caution Regarding Forward Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Talisker’s current belief or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the benefits of listing on the OTCQX Market. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Talisker. Although such statements are based on reasonable assumptions of Talisker’s management, there can be no assurance that any conclusions or forecasts will prove to be accurate. The forward-looking information contained in this release is made as of the date hereof, and Talisker is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to report results from 100 drill holes from its now-complete Phase 2 drill program at the 100%-owned Pardo “River of Gold” Project, located 65 km northeast of Sudbury, Ontario. Results from an additional 89 drill holes remain pending (Figure 1).

The latest drilling continues to strengthen the Company’s view of Pardo as a large, shallow gold system with multiple stacked gold-bearing layers and more than one potential development opportunity.

Drilling has identified several areas of higher-grade gold within the Main Conglomerate Layer (“Main Layer” or “MiBC”), highlighted by 4.96 g/t gold over 2.09 m, including 30.04 g/t gold over 0.33 m in PD-26-348, beginning only 2.72 m from surface.

Importantly, these higher-grade results are being returned from several different areas demonstrating continuity. The Main Layer also contains broader lower-grade mineralization between and around higher-grade intervals, showing that the MiBC itself may have potential beyond the higher-grade material being targeted for direct ship ore (“DSO”) development.

Gold mineralization also occurs within the Matinenda Conglomerate (“MaC”), Upper Conglomerate (“MiPC”) and Upper Sandstone (“MiBS”) layers. Together, the MiBC, MaC, MiPC and MiBS form a shallow, stacked system of multiple gold-bearing layers at Pardo (Figure 2). The Company is advancing the shallow, higher-grade portions of the Main Layer as part of its DSO development strategy, while larger volumes of mineralized material, including lower-grade mineralization across all four layers, are defining a broader bulk-tonnage opportunity.

HIGHLIGHTS

• Multiple areas of shallow, higher-grade Main Layer mineralization continue to demonstrate continuity within the near-surface DSO area, where the Main Layer occurs within approximately 15 metres of surface.
• Main Layer drilling highlights include:
  
  • 4.96 g/t gold over 2.09 m, including 30.04 g/t gold over 0.33 m, beginning only 2.72 m from surface in PD-26-348.
  • 2.48 g/t gold over 3.71 m, including 8.44 g/t gold over 0.97 m and 12.61 g/t gold over 0.50 m in PD-26-332.
  • 1.05 g/t gold over 8.25 m, including 3.01 g/t gold over 2.55 m and 9.49 g/t gold over 0.44 m in PD-26-324.
  • 2.03 g/t gold over 2.42 m, including 4.02 g/t gold over 1.00 m and 5.74 g/t gold over 0.50 m in PD-26-333.
  • 1.38 g/t gold over 4.78 m, including 2.60 g/t gold over 2.35 m and 6.27 g/t gold over 0.43 m in PD-26-359.
  • 2.00 g/t gold over 2.28 m, including 4.00 g/t gold over 1.00 m and 9.31 g/t gold over 0.30 m in PD-26-379.
• Broad lower-grade gold mineralization occurs within the Main Layer itself and within the MaC, MiPC and MiBS layers, showing that gold mineralization at Pardo extends well beyond the higher-grade areas of the Main Layer.
• Examples of broader lower-grade mineralization include:
  
  • 0.54 g/t gold over 3.75 m in the MiBC, including 2.67 g/t gold over 0.43 m, in PD-26-367.
  • 0.23 g/t gold over 5.76 m in the MiBC, including 1.08 g/t gold over 0.50 m, in PD-26-399.
  • 0.81 g/t gold over 2.95 m in the MaC, including 1.33 g/t gold over 1.42 m, in PD-26-305.
  • 0.48 g/t gold over 4.88 m in the MaC, including 0.70 g/t gold over 2.58 m, in PD-26-306.
  • 0.50 g/t gold over 5.92 m in the MiPC, including 1.29 g/t gold over 1.30 m, in PD-26-369.
  • 0.27 g/t gold over 6.71 m in the MiPC and 0.43 g/t gold over 1.70 m in the MiBS in PD-26-375.
  • 0.72 g/t gold over 1.84 m in the MiBS in PD-26-316.

• Gold mineralization also occurs within the Matinenda Conglomerate (“MaC”), Upper Conglomerate (“MiPC”) and Upper Sandstone (“MiBS”) layers. Together, the MiBC, MaC, MiPC and MiBS form a shallow, stacked system of multiple gold-bearing layers at Pardo (Figure 2). The Company believes the higher-grade portions of the Main Layer could support its DSO development strategy, while the broader lower-grade mineralization across all four layers provides additional bulk-tonnage potential. Heap leaching is being evaluated as one potential lower-cost processing option that could further improve the economics of this material.
• Results from an additional 89 drill holes remain pending, with Phase 3 drilling planned to begin in mid-October and the maiden mineral resource estimate planned for Q4 2026.

Wesley Whymark, CEO & Director, comments: “These results continue to build our confidence in Pardo. The Main Layer remains the foundation of our near-term development strategy, and we are seeing strong gold grades across several different areas. PD-26-348 is a great example, returning nearly 5 g/t gold over more than two metres starting less than three metres below surface.”

“What is becoming equally interesting is the amount of lower-grade gold mineralization throughout the system. The Main Layer itself contains broader lower-grade intervals in addition to the higher-grade zones, while the MaC, MiPC and MiBS layers are also returning broad gold-bearing intervals. This means we need to look at Pardo as more than just a single high-grade layer.”

“Our DSO area is defined by how close the Main Layer is to surface, not by where the higher-grade gold ends. Strong Main Layer grades continue below and outside the DSO area, while broader lower-grade mineralization across several layers is building a separate bulk-tonnage opportunity. With 89 drill results pending, Phase 3 drilling starting in mid-October, the maiden resource estimate underway, there is still a lot more to come from Pardo.”

PHASE 2 DRILLING UPDATE

Inventus has now completed its Phase 2 drill program at Pardo. The program targeted the shallow and laterally extensive Main Layer, together with the MiPC, MiBS and MaC layers.

Results from 100 holes are reported in this release (see Tables 1 and 2), with assays from another 89 holes pending.

The latest drilling continues to identify several areas of strong Main Layer mineralization across the property. Hole PD-26-348 returned 4.96 g/t gold over 2.09 m from only 2.72 m depth, including 30.04 g/t gold over 0.33 m. Nearby drilling returned 1.71 g/t gold over 1.43 m in PD-26-345, while PD-26-333 returned 2.03 g/t gold over 2.42 m, including 4.02 g/t gold over 1.00 m.

Another area of strong mineralization is highlighted by PD-26-332, which returned 2.48 g/t gold over 3.71 m, including 8.44 g/t gold over 0.97 m and 12.61 g/t gold over 0.50 m.

Additional Main Layer results include 1.88 g/t gold over 1.42 m in PD-26-358, 1.38 g/t gold over 4.78 m in PD-26-359, and 1.64 g/t gold over 1.55 m in PD-26-366.

Farther north, drilling returned 2.00 g/t gold over 2.28 m in PD-26-379 and 2.34 g/t gold over 1.44 m in PD-26-381.

The drilling also shows that the Main Layer contains a wider range of gold grades than the higher-grade highlights alone suggest. Lower-grade MiBC intervals can extend for several metres, including 0.54 g/t gold over 3.75 m in PD-26-367 and 0.40 g/t gold over 4.28 m in PD-26-337. This broader mineralized material adds to the bulk-tonnage potential at Pardo.

The importance of these results is their distribution. Higher-grade Main Layer mineralization is being intersected in several different parts of the drilled area, supporting the Company’s interpretation of a laterally extensive mineralized layer containing multiple areas of higher-grade gold mineralization. This drilling is helping Inventus better understand the full extent and grade distribution of the gold-bearing layers improving confidence ahead of the planned maiden mineral resource estimate. With Phase 2 drilling now complete, Phase 3 drilling is planned to begin in mid-October 2026.

BROAD LOWER-GRADE MINERALIZATION AND BULK-TONNAGE POTENTIAL

One of the more important developments from Phase 2 drilling is the amount of lower-grade gold mineralization being identified throughout the Pardo system.

This mineralization is not limited to the layers above and below the Main Layer. The MiBC itself contains both higher-grade zones and broader lower-grade intervals. This is important because it increases the amount of mineralized material that could potentially be considered in a larger-scale development scenario, beyond the shallow part of higher-grade material currently being advanced for DSO development.

The MaC layer also continues to return encouraging results, including 0.81 g/t gold over 2.95 m in PD-26-305, including 1.33 g/t gold over 1.42 m, and 0.48 g/t gold over 4.88 m in PD-26-306, including 0.70 g/t gold over 2.58 m.

These results build on previously reported drilling that demonstrated the MaC can also contain higher-grade gold (see news release July 6, 2026). The MaC therefore has potential both as a source of broader lower-grade mineralization and as another layer capable of hosting higher-grade gold.

The MiPC layer is particularly interesting because of its thickness and shallow position. Recent results include 0.50 g/t gold over 5.92 m in PD-26-369, including 1.29 g/t gold over 1.30 m, 0.40 g/t gold over 4.63 m in PD-26-368, 0.32 g/t gold over 4.67 m in PD-26-320, and 0.27 g/t gold over 6.71 m in PD-26-375. Other MiPC intersections have been observed to exceed seven and eight metres in thickness.

The MiBS layer has also returned gold mineralization, including 0.72 g/t gold over 1.84 m in PD-26-316, 0.43 g/t gold over 1.70 m in PD-26-375, and 0.34 g/t gold over 3.04 m in PD-26-429. Together, the results demonstrate that Pardo is not simply a single gold-bearing layer. It is a shallow, stacked system where gold occurs across several layers and across a range of grades.

The broader lower-grade mineralization within the MiBC, MaC, MiPC and MiBS layers is defining a significant bulk-tonnage opportunity at Pardo that is expected to be further outlined in the upcoming maiden mineral resource estimate. The shallow, flat-lying geometry of these stacked gold-bearing layers is particularly important because they occur close together, near surface and could potentially be accessed within the same development area.

Earlier heap-leach test work at Pardo returned very encouraging gold recoveries (see news release August 6, 2026), and the Company is continuing to evaluate heap leaching as a potential lower-cost processing method for this material. If further testing continues to support these results, heap leaching could improve the economics of a future bulk-tonnage operation, but the bulk-tonnage potential itself is not dependent on this processing method. Together, the shallow higher-grade DSO potential of the Main Layer and the broader bulk-tonnage opportunity across multiple gold-bearing layers continue to expand the scale and development potential of Pardo.

NEXT STEPS

• Complete and report assays from the 89 drill holes currently pending.
• Incorporate Phase 2 drilling results into the geological model for the planned maiden mineral resource estimate.
• Commence Phase 3 drilling in mid-October 2026 to further expand the footprint of gold mineralization.
• Advance the shallow higher-grade portions of the Main Layer including the ore sorting test work and incorporated into a preliminary economic assessment for the Company’s planned DSO development strategy.
• Continue metallurgical test work on the lower-grade mineralization from the MiBC, MaC, MiPC and MiBS layers including heap leaching.
• Evaluate the potential for the stacked gold-bearing layers to increase the overall scale and development strategy at Pardo.

For further information visit www.inventusmining.com, or contact:

Wesley Whymark
CEO & Director
Inventus Mining Corp.
E-mail: wesley@inventusmining.com
Phone: 705-822-3005

Social Media Accounts

X: https://x.com/InventusMining
LinkedIn: https://ca.linkedin.com/company/inventus-mining
YouTube: https://www.youtube.com/@inventusmining
Facebook: https://www.facebook.com/profile.php?id=61587627317147

Figure 1. Plan map showing Phase 2 drill holes with reported assays in red and holes with pending assays in green.

Figure 2. Simplified geological section illustrating the shallow, stacked gold-bearing layers at the Pardo “River of Gold” Project, including the MiPC, MiBS, Main Layer (MiBC) and Matinenda Layer (MaC).

Table 1. Recent Phase 2 Drilling Assay Highlights.

Drill Hole	From (Metres)	To (Metres)	Zone1	Interval2 (Metres)	Gold Grade (g/t)
PD-26-301	25.86	31.07	MiBC-MaC	5.21	0.43
PD-26-302	30.50	32.51	MiBC-MaC	2.01	0.94
Including	30.95	31.25	MiBC	0.30	4.35
PD-26-304	28.74	32.34	MaC	3.60	0.51
Including	30.96	31.34	MaC	0.38	1.20
PD-26-305	30.47	33.42	MaC	2.95	0.81
Including	32.00	33.42	MaC	1.42	1.33
Including	32.42	32.92	MaC	0.50	2.58
PD-26-306	28.50	33.38	MaC	4.88	0.48
Including	29.92	32.50	MaC	2.58	0.70
PD-26-308	2.67	9.89	MiPC	7.22	0.20
and	12.24	14.68	MiBS	2.44	0.20
PD-26-309	3.63	7.78	MiPC	4.15	0.25
PD-26-312	0.64	4.25	MiPC	3.61	0.35
PD-26-313	0.23	5.03	MiPC	4.80	0.23
PD-26-314	0.68	6.31	MiPC	5.63	0.24
PD-26-315	0.31	8.76	MiPC	8.45	0.16
and	13.45	14.88	MiBS	1.43	0.37
and	25.70	28.70	MiBC	3.00	0.28
and	35.23	37.64	MiBC	2.41	0.23
PD-26-316	0.15	7.43	MiPC	7.28	0.20
and	19.00	20.84	MiBS	1.84	0.72
and	25.03	29.24	MiBC	4.21	0.32
and	31.75	34.22	MiBC	2.47	0.22
PD-26-317	0.50	2.37	MiPC	1.87	0.24
and	29.76	32.21	MiBC	2.45	0.32
and	37.10	40.81	MiBC	3.71	0.46
Including	39.50	40.50	MiBC	1.00	1.21
PD-26-318	0.75	6.83	MiPC	6.08	0.23
and	25.61	30.50	MiBC	4.89	0.21
and	37.86	41.09	MiBC	3.23	0.55
Including	38.82	39.24	MiBC	0.42	1.47
PD-26-319	0.50	8.50	MiPC	8.00	0.23
and	31.61	43.10	MiBC	11.49	0.23
PD-26-320	0.66	5.33	MiPC	4.67	0.32
and	37.90	40.73	MiBC	2.83	1.23
Including	39.38	40.73	MiBC	1.35	2.44
Including	40.23	40.73	MiBC	0.50	5.21
PD-26-322	5.40	10.87	MiPC	5.47	0.32
and	15.78	17.39	MiBC	1.61	1.60
Including	16.23	17.00	MiBC	0.77	2.62
PD-26-323	9.62	14.74	MiPC	5.12	0.26
and	22.25	25.56	MiBC	3.31	0.29
PD-26-324	14.30	22.55	MiBC	8.25	1.05
Including	20.00	22.55	MiBC	2.55	3.01
Including	20.93	21.37	MiBC	0.44	9.49
PD-26-325	14.52	19.55	MiBC	5.03	0.30
PD-26-326	6.70	10.08	MiBC	3.38	0.76
Including	8.62	10.08	MiBC	1.46	1.26
Including	9.72	10.08	MiBC	0.36	3.26
PD-26-327	7.65	12.26	MiBC	4.61	0.63
Including	10.50	12.26	MiBC	1.76	1.43
Including	11.00	11.43	MiBC	0.43	3.83
PD-26-328	9.76	12.15	MiBC	2.39	1.02
Including	11.16	11.80	MiBC	0.64	2.71
PD-26-329	6.89	9.33	MiBC	2.44	0.70
Including	8.89	9.33	MiBC	0.44	1.34
PD-26-332	7.95	11.66	MiBC	3.71	2.48
Including	9.24	10.21	MiBC	0.97	8.44
Including	9.24	9.74	MiBC	0.50	12.61
PD-26-333	4.00	6.42	MiBC	2.42	2.03
Including	4.93	5.93	MiBC	1.00	4.02
Including	4.93	5.43	MiBC	0.50	5.74
PD-26-335	5.40	6.49	MiBC	1.09	1.86
PD-26-337	9.30	12.88	MiPC	3.58	0.25
and	29.00	33.28	MiBC	4.28	0.40
Including	29.50	30.00	MiBC	0.50	1.29
PD-26-338	6.00	8.54	MiPC	2.54	0.33
and	30.12	34.10	MiBC	3.98	0.30
PD-26-339	28.90	32.32	MiBC	3.42	0.40
Including	31.88	32.32	MiBC	0.44	1.85
PD-26-342	3.03	4.96	MiPC	1.93	0.34
PD-26-345	3.35	4.78	MiBC	1.43	1.71
Including	3.35	3.85	MiBC	0.50	3.56
PD-26-348	2.72	4.81	MiBC	2.09	4.96
Including	2.72	3.05	MiBC	0.33	30.04
PD-26-349	1.75	2.68	MiBC	0.93	0.95
PD-26-354	0.00	0.75	MiBC	0.75	1.38
PD-26-355	1.00	1.75	MiBC	0.75	2.12
PD-26-356	0.71	4.95	MiBC	4.24	1.02
Including	2.95	4.44	MiBC	1.49	2.34
Including	3.31	3.61	MiBC	0.30	6.13
PD-26-357	1.25	3.67	MiBC	2.42	0.41
PD-26-358	8.70	10.12	MiBC	1.42	1.88
Including	9.33	10.12	MiBC	0.79	3.14
Including	9.73	10.12	MiBC	0.39	4.96
PD-26-359	5.48	10.26	MiBC	4.78	1.38
Including	7.07	9.42	MiBC	2.35	2.60
Including	7.07	7.50	MiBC	0.43	6.27
PD-26-362	11.60	13.23	MiBC	1.63	0.51
Including	12.45	12.76	MiBC	0.31	1.73
PD-26-363	9.75	12.32	MiBC	2.57	1.08
Including	10.15	10.50	MiBC	0.35	3.57
PD-26-364	9.29	12.19	MiBC	2.90	0.41
PD-26-365	2.97	4.65	MiPC	1.68	0.26
and	12.95	14.76	MiBC	1.81	2.23
Including	13.81	14.76	MiBC	0.95	4.00
PD-26-366	11.12	12.67	MiBC	1.55	1.64
Including	11.40	11.78	MiBC	0.38	2.97
PD-26-367	41.58	45.33	MiBC	3.75	0.54
Including	44.90	45.33	MiBC	0.43	2.67
PD-26-368	6.37	11.00	MiPC	4.63	0.40
and	17.53	19.95	MiBC	2.42	0.21
and	30.09	32.06	MiBC	1.97	0.56
PD-26-369	11.21	17.13	MiPC	5.92	0.50
Including	11.87	13.17	MiPC	1.30	1.29
and	25.80	29.70	MiBC	3.90	0.24
PD-26-370	13.00	18.08	MiPC	5.08	0.30
Including	13.89	14.20	MiPC	0.31	1.07
PD-26-371	10.31	13.85	MiPC	3.54	0.32
and	20.00	24.38	MiBC	4.38	0.21
PD-26-372	11.64	12.83	MiPC	1.19	1.14
and	15.62	17.02	MiPC	1.40	0.31
and	24.41	28.36	MiPC	3.95	0.37
Including	24.91	25.41	MiPC	0.50	1.28
and	47.30	50.65	MiBC	3.35	0.87
Including	47.76	49.27	MiBC	1.51	1.62
Including	47.76	48.11	MiBC	0.35	3.91
PD-26-373	10.48	14.55	MiPC	4.07	0.28
PD-26-375	7.79	14.50	MiPC	6.71	0.27
and	17.98	19.68	MiBS	1.70	0.43
PD-26-377	34.45	37.38	MiBC	2.93	0.98
Including	37.07	37.38	MiBC	0.31	7.67
PD-26-378	1.74	3.32	MiPC	1.58	0.23
and	11.50	12.48	MiBC	0.98	1.62
Including	12.12	12.48	MiBC	0.36	3.30
PD-26-379	7.62	9.90	MiBC	2.28	2.00
Including	8.42	9.42	MiBC	1.00	4.00
Including	8.42	8.72	MiBC	0.30	9.31
PD-26-381	14.04	15.48	MiBC	1.44	2.34
Including	14.66	15.11	MiBC	0.45	4.60
PD-26-382	7.61	8.73	MiBC	1.12	1.37
Including	8.11	8.43	MiBC	0.32	3.15
PD-26-383	7.74	12.26	MiBC	4.52	0.94
Including	10.76	12.26	MiBC	1.50	2.48
Including	11.26	11.76	MiBC	0.50	4.78
PD-26-385	7.00	8.75	MiBC	1.75	0.36
PD-26-387	14.00	15.93	MiBC	1.93	0.38
PD-26-391	36.01	37.63	MiBC	1.62	0.38
PD-26-392	2.00	4.00	MiPC	2.00	0.26
and	8.00	12.06	MiPC	4.06	0.25
and	31.10	35.44	MiBC	4.34	0.32
and	37.63	40.10	MaC	2.47	0.35
PD-26-396	7.52	11.95	MiPC	4.43	0.25
and	27.00	29.00	MiBS	2.00	0.22
and	31.05	34.58	MiBC	3.53	0.28
and	37.47	39.42	MaC	1.95	0.26
PD-26-397	38.59	41.40	MiBC	2.81	0.89
Including	39.09	39.50	MiBC	0.41	3.32
PD-26-399	14.71	18.17	MiPC	3.46	0.33
Including	15.67	16.17	MiPC	0.50	1.29
and	36.00	41.76	MiBC	5.76	0.23
Including	36.44	36.94	MiBC	0.50	1.08
and	40.28	41.76	MiBC	1.48	0.25
PD-26-426	27.30	33.90	MiBS-MiBC	6.60	0.40
Including	32.00	33.90	MiBC	1.90	0.66
PD-26-427	6.90	9.60	MiPC	2.70	0.32
and	34.60	38.77	MiBC	4.17	0.25
PD-26-429	29.06	32.10	MiBS	3.04	0.34

¹ MiBC – Main Layer; MaC – Matinenda Layer; MiPC – Upper Conglomerate Layer; MiBS – Upper Sandstone.
²Interval width is approximate true thickness. Mineralization has a flat to 5-degree dip, and all holes were drilled vertically with an inclination of -90 degrees.

Table 2. Details of Phase 2 drill hole locations reported.

Drill Hole	Inclination (Degrees)	Length (Metres)	Northing (UTM)	Easting (UTM)
PD-26-301	-90	34.00	5183157	555814
PD-26-302	-90	38.50	5183138	555836
PD-26-303	-90	40.00	5183162	555837
PD-26-304	-90	38.50	5183190	555837
PD-26-305	-90	41.50	5183221	555839
PD-26-306	-90	36.50	5183251	555837
PD-26-307	-90	58.00	5183326	555911
PD-26-308	-90	56.50	5183272	555909
PD-26-309	-90	50.50	5183219	555896
PD-26-310	-90	46.00	5183162	555898
PD-26-311	-90	43.00	5183107	555896
PD-26-312	-90	47.50	5183109	555951
PD-26-313	-90	49.00	5183159	555955
PD-26-314	-90	58.00	5183220	555956
PD-26-315	-90	50.50	5183275	555967
PD-26-316	-90	49.00	5183176	555983
PD-26-317	-90	44.50	5183234	555991
PD-26-318	-90	43.00	5183259	556002
PD-26-319	-90	46.00	5183319	556025
PD-26-320	-90	43.00	5183284	556016
PD-26-321	-90	53.50	5183327	555966
PD-26-322	-90	19.00	5183135	556023
PD-26-323	-90	26.50	5183161	556012
PD-26-324	-90	25.00	5183221	556037
PD-26-325	-90	23.50	5183262	556058
PD-26-326	-90	12.00	5183448	556335
PD-26-327	-90	13.50	5183449	556320
PD-26-328	-90	15.29	5183432	556321
PD-26-329	-90	15.00	5183419	556337
PD-26-330	-90	13.50	5183415	556326
PD-26-331	-90	18.00	5183360	556306
PD-26-332	-90	13.50	5183347	556291
PD-26-333	-90	11.50	5183206	556443
PD-26-334	-90	13.00	5183189	556476
PD-26-335	-90	10.00	5183213	556512
PD-26-336	-90	40.00	5183197	556566
PD-26-337	-90	43.16	5183323	556667
PD-26-338	-90	44.50	5183237	556599
PD-26-339	-90	47.00	5183277	556663
PD-26-340	-90	49.00	5183277	556614
PD-26-341	-90	48.45	5183240	556662
PD-26-342	-90	49.00	5183196	556627
PD-26-343	-90	6.00	5183355	556467
PD-26-344	-90	6.00	5183367	556483
PD-26-345	-90	7.50	5183353	556485
PD-26-346	-90	7.50	5183368	556495
PD-26-347	-90	9.00	5183353	556495
PD-26-348	-90	10.50	5183338	556497
PD-26-349	-90	7.50	5183318	556495
PD-26-350	-90	10.50	5183336	556510
PD-26-351	-90	7.50	5183353	556512
PD-26-352	-90	7.50	5183368	556515
PD-26-353	-90	7.50	5183383	556511
PD-26-354	-90	5.50	5183315	556455
PD-26-355	-90	4.50	5183304	556454
PD-26-356	-90	6.00	5183281	556455
PD-26-357	-90	7.50	5183290	556453
PD-26-358	-90	12.00	5183370	556205
PD-26-359	-90	13.50	5183376	556175
PD-26-360	-90	13.50	5183383	556161
PD-26-361	-90	16.50	5183381	556147
PD-26-362	-90	17.00	5183407	556162
PD-26-363	-90	16.50	5183411	556146
PD-26-364	-90	15.00	5183425	556162
PD-26-365	-90	16.50	5183440	556146
PD-26-366	-90	15.00	5183439	556163
PD-26-367	-90	51.00	5183071	556539
PD-26-368	-90	44.50	5183018	556539
PD-26-369	-90	50.50	5182961	556535
PD-26-370	-90	55.10	5182900	556533
PD-26-371	-90	41.50	5182841	556533
PD-26-372	-90	55.10	5182773	556587
PD-26-373	-90	52.00	5182840	556596
PD-26-374	-90	55.10	5182897	556596
PD-26-375	-90	53.50	5182959	556597
PD-26-376	-90	48.71	5183009	556619
PD-26-377	-90	49.00	5183079	556602
PD-26-378	-90	15.00	5183449	556193
PD-26-379	-90	13.50	5183460	556208
PD-26-380	-90	19.50	5183461	556226
PD-26-381	-90	18.00	5183461	556243
PD-26-382	-90	10.50	5183464	556261
PD-26-383	-90	13.50	5183446	556309
PD-26-384	-90	12.00	5183448	556290
PD-26-385	-90	10.50	5183449	556274
PD-26-386	-90	15.00	5183451	556257
PD-26-387	-90	18.00	5183447	556227
PD-26-391	-90	47.50	5183137	556628
PD-26-392	-90	41.67	5183271	556709
PD-26-393	-90	34.00	5183244	556905
PD-26-394	-90	35.29	5183364	556874
PD-26-395	-90	25.09	5183309	556904
PD-26-396	-90	41.50	5183240	556708
PD-26-397	-90	55.50	5183080	556676
PD-26-398	-90	50.50	5183139	556671
PD-26-399	-90	52.00	5183202	556674
PD-26-426	-90	46.00	5183139	556726
PD-26-427	-90	41.50	5183193	556732
PD-26-428	-90	44.50	5183084	556725
PD-26-429	-90	49.00	5183018	556722

About Inventus Mining Corp.

Inventus is a mineral exploration and development company focused on the world-class mining district of Sudbury, Ontario. We have a 100% interest in our principal assets, the Pardo Paleoplacer Gold Project and the Sudbury 2.0 Critical Mineral Project, located northeast of Sudbury. The Pardo Gold Project is the first important paleoplacer gold discovery in North America. Inventus has approximately 221 million common shares outstanding.

Qualified Person

The Qualified Person responsible for the technical content of this news release is Wesley Whymark, P.Geo., who has reviewed and approved the technical disclosure in this news release on behalf of the Company.

Technical Information

Drill core samples collected by Inventus and described in this news release were subject to robust QA/QC protocols. PQ-size drill core was placed in core boxes by the contracted drill crew and then transported by Inventus personnel to a secure processing facility in Sudbury, Ontario. The core was reviewed, with core metreage blocks checked to verify core integrity and recovery, geologically logged, and sample intervals marked. Whole-core samples were then photographed and inserted into clean plastic bags with sample tags. Certified reference materials were inserted into the sample stream at a rate of no less than 10%.

Samples were then transported in secure sealed bags with security tags for preparation and assay by MSA Labs or Paragon Geochemical in Timmins, Ontario. Samples were processed, whereby the entire sample was crushed to 80% passing 2 mm and then riffle split into two (2) or three (3) 300- to 500-g jars for gold analysis by PhotonAssay. Duplicate or triplicate samples were analyzed, and the results averaged. MSA Labs and Paragon Geochemical are both an ISO 17025:2017 accredited geochemical testing laboratory.

Forward-Looking Statements

This News Release includes certain “forward-looking statements” which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “if”, “yet”, “potential”, “undetermined”, “objective”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to the failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR+. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/b60ffb62-bdcd-4a06-8cbf-403a1fc2e987
https://www.globenewswire.com/NewsRoom/AttachmentNg/df69534d-ec0e-4939-97ea-e9ea6d26f743

John Chambers, PhD, and Nilanjana Sadhu, PhD, to share early insights from pioneering population-scale proteomic study of 10,000 participants in Singapore

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Convention & Exhibition Centre.

Led by John Chambers, PhD, Chief Scientific Officer of PRECISE and Lead PI of PRECISE-SG100K, the study represents an ambitious effort to bring deep molecular characterization to population health at unprecedented scale. By integrating proteomic data with genomic, clinical and phenotypic information from Singapore’s multi-ethnic population, PRECISE-SG100K is creating a uniquely rich resource for understanding how biological and population-level differences contribute to health and disease.

As the PRECISE-SG100K program evolved, the investigators expanded its proteomic strategy to include deep, unbiased mass spectrometry-based profiling in 10,000 participants. This complementary arm of the study combines Seer’s Proteograph® Product Suite with high-performance liquid chromatography-mass spectrometry (LC-MS), enabling researchers to interrogate the circulating proteome across a broad dynamic range and at peptide-level resolution. The approach provides an important discovery dimension to the study, allowing investigators to look beyond predefined protein targets and explore biological signals that may not have been anticipated at the outset.

In April 2026, Seer announced that the Proteograph Product Suite had been selected for this 10,000-participant component of PRECISE-SG100K. By enriching proteins across the enormous dynamic range of plasma before mass spectrometry analysis, Proteograph can increase the depth of protein coverage by approximately 7 to 10-fold compared with direct plasma analysis on leading mass spectrometry platforms. That additional depth brings into view lower-abundance proteins and potential biomarkers that can otherwise go undetected, while preserving the peptide-level information needed to investigate protein variants and other molecular differences.

For population-scale studies, depth alone is not enough. Biological signals must also be measured robustly and reproducibly across thousands of samples. The Proteograph workflow is designed to deliver consistent sample processing and high-quality proteomic data at scale, helping investigators distinguish meaningful biological variation from technical variability and increasing confidence in the signals identified across the cohort.

“As biology enters the AI era, the value of our models will ultimately depend on the richness and resolution of the biological data we can generate,” said Omid Farokhzad, Chair and Chief Executive Officer of Seer. “Proteins are the functional layer of biology, yet the plasma proteome spans an extraordinary dynamic range, and many potentially important disease signals are present at low abundance. Proteograph changes what mass spectrometry can see. John Chambers and the PRECISE-SG100K team have created a pioneering study that brings together population scale, diversity and deep, peptide-resolved proteomics in a way that can uncover biology that might otherwise remain hidden.”

“The combination of Proteograph enrichment and high-performance mass spectrometry has allowed us to interrogate the circulating proteome with a level of depth, consistency and reproducibility, and to bring deep biological resolution to population-scale analysis,” said John Chambers, PhD, Chief Scientific Officer of PRECISE and Lead PI of the PRECISE-SG100K study. “The proteomic data generated using this technology are already revealing proteogenomic and epidemiological signals and show strong potential to accelerate biomarker discovery and broaden the reach of precision medicine.”

Seer Breakfast Symposium

Mass Spectrometry-based Proteomics in Asian Cohort Studies: Opportunities and Challenges

Date: Monday, September 28, 2026 | Time: 7:45-8:45 a.m. SGT | Location: Room 330, Level 3

Speakers:

John Chambers, PhD, Professor, Nanyang Technological University, Singapore; Chief Scientific Officer of PRECISE and Lead PI of the PRECISE-SG100K study

Nilanjana Sadhu, PhD, Research Assistant Professor, Nanyang Technological University, Singapore; Proteomic Working Group Lead of the PRECISE-SG100K study

The PRECISE-SG100K study is a landmark effort in precision health, designed to capture genetic, molecular, clinical and phenotypic diversity across Singapore’s multi-ethnic population. As part of its broader proteomic strategy, the study incorporated the Seer Proteograph workflow combined with Thermo Scientific Orbitrap Astral™ mass spectrometry to deeply characterize the circulating proteome of 10,000 individuals. Early proteogenomic and epidemiological findings will provide a first look at the additional biological insights enabled by deep, unbiased, mass spectrometry-based proteomics at population scale.

Seer Poster Presentation

From Peaks to Power: Context-Driven Determinants of Accuracy in Large-Scale Proteomics

Date: Wednesday, September 30, 2026 | Time: 1:15 p.m. SGT | Location: Exhibit Hall | Session: PS03.002

Presenter: Lee Cantrell, Bioinformatics Scientist III, Seer

Authors: Lee Cantrell, Seth Just, Serafim Batzoglou

Population-scale proteomics creates the opportunity to make statistically powered, in-depth biological observations across large cohorts. Realizing that opportunity requires more than depth alone: quantitative fidelity and reproducibility must be maintained as studies scale. This poster examines the acquisition context required to preserve biological signal across large numbers of samples and what those requirements mean for the design of large clinical and population studies.

Together, the presentations illustrate both the scientific ambition and the technical requirements of a new generation of population proteomics studies. PRECISE-SG100K demonstrates what becomes possible when deep, peptide-resolved mass spectrometry is incorporated into a richly characterized, multi-ethnic population cohort, while From Peaks to Power examines what is required to preserve quantitative fidelity as studies reach this scale. Together, they point toward proteomic datasets with the breadth, depth and reproducibility needed to support biomarker discovery, population health research and increasingly data-intensive approaches to biology.

For more information, please visit Booth #232 at the HUPO World Congress.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

About PRECISE-SG100K Study

The PRECISE-SG100K study is a landmark, long-term research project that has completed recruitment of over 100,000¹ participants from Singapore’s diverse, multi-ethnic population. The study has collected extensive baseline health information and biological specimens and will continue to monitor long-term health outcomes and the environmental, lifestyle and genetic factors associated with diseases such as diabetes, hypertension and cancer. As one of the largest population health studies in Southeast Asia, PRECISE-SG100K is designed to advance precision medicine and improve health outcomes for diverse populations worldwide.

For more information, visit www.npm.sg.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations about the PRECISE-SG100K collaboration, population-scale proteomics studies, and the impact of Seer’s products. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact

Patrick Schmidt
pr@seer.bio

Investor Contact

Marissa Bych
investor@seer.bio

______________________________
¹ NTD: Above we say 10,000 individuals. Confirm this 100,000 figure is distinct.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce the increase and closing of the second and final tranche (the “Second Tranche”) of its private placement (the “Offering”) previously announced on August 20, 2026. Gross proceeds from the Second Tranche totalled CAD $520,000, consisting of $270,000 from the sale of 675,000 units at $0.40 (the “Equity Units”) and $250,000 from the sale of unsecured convertible debenture units (the “Debenture Units”). The private placement of Equity Units and Debenture Units is collectively referred as the Offering. The first tranche of the Offering closed on September 9, 2026 totalling CAD $600,000, consisting of $285,000 from the sale of 712,500 Equity Units and $315,000 from the sale of Debenture Units. With the closing of the Second Tranche, the Offering has now closed for total proceeds of $1,120,000.

Each Equity Unit, at an issue price of CAD $0.40, consists of one Class A common share in the capital of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant entitles the holder to acquire one Common Share (a “Warrant Share“) at an exercise price of CAD $0.60 (the “Exercise Price“) per Warrant Share for a period of 36 months from the issuance date (the “Expiry Date“).

Each Debenture Unit consists of one debenture (a “Convertible Debenture”) in the principal amount of CAD $1,000 and 2,198 common share purchase warrants (a “Debenture Warrant”). The Convertible Debentures carry interest at a rate of 10% per annum from the closing date, payable semi-annually in arrears until the maturity date, which will be 24 months from the closing date of the Convertible Debentures or the conversion date of the Debentures. The outstanding principal and interest can be converted, at the option of the Convertible Debenture holder, into Common Share at a fixed price of CAD $0.455 per Common Share on or before the maturity date of the Convertible Debenture. The Company may from time to time, in its sole discretion, prepay all or a part of the principal amount and accrued interest without penalty. Each Debenture Warrant entitles the holder to acquire one Common Share (a “Debenture Warrant Share”) at an exercise price of CAD $0.55 per Debenture Warrant Share for a period of 36 months from the date of issuance.

The Company did not pay any cash finder’s fees or issue finders warrants to eligible finders in regards to the Second Tranche of the Offering.

The Company will use the proceeds of the Offering to advance its Alzheimer’s Disease program towards the opening of U.S. brain-specific neuroimaging clinic, general and administrative expenses, and for working capital purposes.

The securities issued and issuable, described in this and the previous news releases from August 20, 2026, September 10, 2026 and September 16, 2026, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration.

For more information please contact:

Christopher J. Moreau
CEO
Grey Matters Health Inc.
604.398.4175 Ext 701

cjmoreau@greymatters-health.com
info@greymatters-health.com
www.greymatters-health.com

About Grey Matters  

Grey Matters is a Canadian healthcare company focused on the provision of brain dedicated PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease and other forms of neurodegenerative diseases, including frontotemporal dementia, Lewy body dementia, and will additionally offer other select neuro-oncology imaging applications too.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Today, Loblaw released the latest edition of its Food Inflation Report, following Statistics Canada’s release of August CPI data. While grocery inflation slowed to 2.8% year over year, falling below overall inflation for the first time in more than a year, affordability remains a significant challenge for many Canadians. 

This month’s report examines several emerging pressures that could influence food costs in the months ahead, including El Niño, commodity volatility, seafood supply constraints and the latest Canada-U.S. tariff measures. It also outlines how Loblaw is responding by helping customers identify tariff-affected products, highlighting Canadian-made and Canadian-prepared products where possible, and continuing to source competitively to deliver value. 

For more information, contact pr@loblaw.ca.

• All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated
• Strong immunogenicity demonstrated, with 100% response rate after three immunizations
• Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement
• Discussions with FDA regarding future development path planned for early 2027
• AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below

Lausanne, Switzerland, September 23, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson’s disease (PD). The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity as the basis for a Phase 3 decision. The Part 1 data reported today includes results from all 34 patients randomized into the study (25 patients receiving ACI-7104 and nine receiving placebo).

The primary endpoints for Part 1 of the VacSYn trial of ACI-7104 were safety, tolerability and immunogenicity, all of which were met. ACI-7104 was generally safe and well-tolerated and shown to be strongly immunogenic, with 100% of patients developing antibodies against the immunizing a-syn target antigen PD01 after three immunizations. Antibody reactivity against the aggregated species of a-syn was also demonstrated. Robust antibody penetration into the cerebrospinal fluid (CSF) was observed in all patients.

Part 1 of VacSYn was not designed for biomarker or clinical outcomes evaluation; however, additional exploratory analyses included monitoring the impact of ACI-7104 treatment on certain biomarkers (such as total a-syn and Neurofilament Light chain in the CSF), as well as clinical measures of disease activity. A signal was observed for total a-syn in the CSF, providing preliminary evidence consistent with target engagement. Exploratory correlation analyses identified trends suggesting an association between immunogenicity (antibody levels) and disease activity measures. While the sample size in Part 1 was limited, these observations provide a clear basis for further investigation.

The VacSYn trial of ACI-7104 in early-stage Parkinson’s disease continues in Part 1 (2-year extension) and is advancing toward the initiation of Part 2 (expansion). The final design of Part 2 is being consolidated and will be submitted to the FDA for review, with meetings expected early in 2027.

Martin Zügel, Interim CEO of AC Immune SA, commented: “The results from the complete data set at week-100 in Part 1 are encouraging, with all primary endpoints met, strong immunogenicity demonstrated, and a 100% response rate. This program is one of our strongest active immunotherapies, with ACI-7104-induced antibodies demonstrating preferential binding to aggregated a-syn species. We will now refine our approach to the next development steps in the program and discuss our plans with regulators before embarking on an expanded Phase 2 trial designed to provide evidence of clinical activity as the basis for entry into Phase 3.”

Günther Staffler, Executive Vice President, Development at AC Immune SA, commented: “We are pleased to have observed strong and boostable immune responses, with significant antibody penetration into the CSF and signals for target engagement. Together with the favorable safety profile through week-100, and exploratory correlations between antibody titers and disease activity measures, we are confident that these results provide a strong foundation for the continued development of ACI-7104 into Part 2.”

Conference call details:
Participants may call the following numbers, 10 – 15 minutes before conference start

Switzerland / Europe:    +41 (0) 58 310 50 00

United Kingdom:           +44 (0) 203 059 58 63

United States:               +1 (1) 631 570 56 13

HD Web Phone™:        Click Here

Other international numbers available HERE

Webcast link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=lUHjSJWK

A live and archived webcast will also be accessible in the Investors section of the Company’s website at https://www.acimmune.com/.

Ends

For further information, please contact:

SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com
International Media Optimum Strategic Communications Nick Bastin, Joshua Evans, Aoife Minihan, Ben Cowe Phone: +44 (0) 20 4566 8543 Email: acimmune@optimumcomms.com

About VacSYn

VacSYn (ClinicalTrials.gov: NCT06015841) is an adaptive, randomized, double-blind, placebo-controlled, and biomarker-based Phase 2 study in patients with early PD, consisting of two parts. Part 1 includes 34 patients randomized 3:1 to receive ACI-7104 or placebo, respectively. The results reported today include data from all participants 100 weeks since initiation of treatment. The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity and support a Phase 3 decision.

About ACI-7104

ACI-7104.056 is an optimized formulation of its clinically validated anti-a-syn predecessor active immunotherapy that generated a target-specific antibody response against pathological oligomeric a-syn to inhibit spreading and downstream neurodegeneration in early Parkinson’s disease. The accumulation of alpha-synuclein protein aggregates has been shown to cause inflammatory stress in cells and contribute to the degeneration of neurons in the brain. It has been known to play a key role in the development of neurodegenerative diseases such as Parkinson’s Disease.

About AC Immune SA 

AC Immune (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company developing a pipeline of products, including both active immunotherapies and small molecules, targeting key misfolded proteins and pathways for the treatment of multiple neurodegenerative diseases. The company has a growing focus on its wholly owned proprietary clinical-stage programs, including: ACI-7104, an active immunotherapy targeting α-synuclein (α-syn) in Parkinson’s disease; and ACI-19764, a small molecule inhibitor of the NLRP3 inflammasome. In addition, an early-stage small molecule development program targeting intracellular a-syn is advancing towards the clinic.

ACIU has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding and >$4.5 billion in potential milestone payments, plus royalties from sales. ACIU’s pharma-partnered programs, all in Alzheimer’s disease, include: a collaboration on ACI-24, an active immunotherapy targeting Abeta; a collaboration on ACI-35 targeting phospho-Tau; and a collaboration developing brain-penetrant small molecule drugs targeting intracellular pathologic Tau.

All trademarks used or mentioned in this release are protected by law. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment

• FINAL__ACIU ACI-7104 Part 1 week 100 VacSYn Phase 2 results PR

• Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12
• Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-1402 in CLE
• IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies
• All other clinical development timelines remain on track

BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).

The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE.

“On behalf of everyone at Immunovant, I want to thank the patients living with CLE who volunteered for this study and the investigators and clinical site teams who conducted it with such care. Their contributions advance our understanding of FcRn inhibition in autoimmune disease and will inform our work going forward,” said Eric Venker, M.D., Pharm.D., Chief Executive Officer of Immunovant.

Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402 across multiple autoimmune diseases with significant unmet need, including Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren’s disease.

About the Proof-of-Concept Study of IMVT-1402 in CLE
The proof-of-concept clinical study (NCT06980805) of IMVT-1402 (imeroprubart) in CLE is a randomized, double-blind, placebo-controlled, global trial that assessed the safety and efficacy of IMVT-1402 in adult patients with CLE. The study enrolled 57 patients. In Period 1, patients were randomized to IMVT-1402 vs. placebo for a 12-week treatment period. The primary endpoint was the percent change from Period 1 baseline in CLASI-A score at Week 12.

About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

About Roivant
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA^™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com